Cutler Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-62,433
| Closed | -$5.79M | – | 3805 |
|
|
2023
Q4 | $5.57M | Buy |
62,433
+29,242
| +88% | +$2.17M | 0.5% | 37 |
|
|
2023
Q3 | $2.42M | Buy |
33,191
+26,310
| +382% | +$2.1M | 0.25% | 92 |
|
|
2023
Q2 | $572K | Sell |
6,881
-17,665
| -72% | -$1.48M | 0.08% | 289 |
|
|
2023
Q1 | $1.87M | Buy |
+24,546
| New | +$2.04M | 0.19% | 104 |
|
|
2022
Q4 | – | Sell |
-120,710
| Closed | -$9.77M | – | 5349 |
|
|
2022
Q3 | $9.57M | Buy |
120,710
+100,796
| +506% | +$8.5M | 0.65% | 12 |
|
|
2022
Q2 | $1.48M | Sell |
19,914
-98,945
| -83% | -$7.43M | 0.1% | 237 |
|
|
2022
Q1 | $10.7M | Buy |
118,859
+32,986
| +38% | +$3.05M | 0.56% | 18 |
|
|
2021
Q4 | $9.61M | Buy |
85,873
+40,609
| +90% | +$4.9M | 0.4% | 37 |
|
|
2021
Q3 | $5.69M | Buy |
+45,264
| New | +$5.83M | 0.26% | 71 |
|
|
2021
Q2 | – | Sell |
-3,000
| Closed | -$394K | – | 6460 |
|
|
2021
Q1 | $406K | Sell |
3,000
-9,852
| -77% | -$1.48M | 0.02% | 847 |
|
|
2020
Q4 | $1.81M | Buy |
+12,852
| New | +$1.65M | 0.09% | 234 |
|
|
2020
Q3 | – | Sell |
-15,752
| Closed | -$1.77M | – | 5331 |
|
|
2020
Q2 | $1.76M | Sell |
15,752
-104,583
| -87% | -$10.3M | 0.12% | 187 |
|
|
2020
Q1 | $9.32M | Buy |
120,335
+39,916
| +50% | +$3.53M | 0.48% | 24 |
|
|
2019
Q4 | $7.65M | Buy |
80,419
+32,980
| +70% | +$2.85M | 0.47% | 34 |
|
|
2019
Q3 | $3.62M | Buy |
47,439
+26,463
| +126% | +$2.2M | 0.33% | 38 |
|
|
2019
Q2 | $1.84M | Buy |
+20,976
| New | +$1.79M | 0.17% | 93 |
|
|
2019
Q1 | – | Sell |
-3,000
| Closed | -$255K | – | 4863 |
|
|
2018
Q4 | $215K | Buy |
+3,000
| New | +$242K | 0.02% | 608 |
|
|
2018
Q3 | – | Sell |
-103,456
| Closed | -$10M | – | 4794 |
|
|
2018
Q2 | $9.85M | Buy |
103,456
+100,556
| +3,467% | +$9.24M | 0.79% | 17 |
|
|
2018
Q1 | $254K | Sell |
2,900
-6,771
| -70% | -$618K | 0.02% | 697 |
|
|
2017
Q4 | $820K | Sell |
9,671
-11,664
| -55% | -$977K | 0.03% | 379 |
|
|
2017
Q3 | $1.85M | Buy |
21,335
+17,848
| +512% | +$1.43M | 0.07% | 215 |
|
|
2017
Q2 | $269K | Buy |
3,487
+800
| +30% | +$56.7K | 0.01% | 1060 |
|
|
2017
Q1 | $186K | Sell |
2,687
-4,387
| -62% | -$295K | 0.01% | 1250 |
|
|
2016
Q4 | $418K | Buy |
7,074
+3,658
| +107% | +$226K | 0.02% | 788 |
|
|
2016
Q3 | $226K | Sell |
3,416
-77,448
| -96% | -$4.79M | 0.01% | 1105 |
|
|
2016
Q2 | $4.37M | Buy |
80,864
+76,045
| +1,578% | +$4.17M | 0.22% | 66 |
|
|
2016
Q1 | $248K | Sell |
4,819
-53,622
| -92% | -$2.79M | 0.02% | 884 |
|
|
2015
Q4 | $4.09M | Buy |
+58,441
| New | +$3.99M | 0.23% | 65 |
|
Other funds holding XBI
ACA
Cutler Group's XBI Position: Q1 2024 in Review
Cutler Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 62,433 shares — an estimated $5.79M sold.
Cutler Group first reported a position in XBI in Q4 2015 and held it in 28 quarters. The position peaked at $10.7M in Q1 2022. 781 funds tracked by Wall St. Rank hold XBI as of Q1 2024.
- Cutler Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
- Cutler Group sold 62,433 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $5.79M.
- Cutler Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and held it in 28 quarters.
- Cutler Group's State Street SPDR S&P Biotech ETF position peaked at $10.7M in Q1 2022.
- 781 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.